Georgia General Assembly · Full text

HB 473: Controlled substances; Schedule I; provide certain provisions

Enrolled version, the latest LegiScan holds · Last action May 1, 2025 · Passed

The text as LegiScan holds it, read from the PDF the legislature publishes with its margin line numbers, running heads, and page footers removed. Line breaks are joined into paragraphs here; no word is changed.

Underlined words are what the bill adds to current law and struck-through words are what it removes, as the printed bill shows them.

Copy for LLM, View as markdown, and Send to AI use the Markdown version: this text, then the summaries under a heading that names them as ours. View raw is the text alone.

Back to the summary

House Bill 473 (AS PASSED HOUSE AND SENATE)

By: Representatives Stephens of the 164th, Hawkins of the 27th, and Newton of the 127th

A BILL TO BE ENTITLED

AN ACT

To amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled substances, so as to provide for certain provisions relating to Schedule I controlled substances; to provide for certain provisions relating to the definition of dangerous drugs; to provide for related matters; to provide for an effective date; to repeal conflicting laws; and for other purposes.

BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:

SECTION 1.

Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled substances, is amended in Code Section 16-13-25, relating to Schedule I controlled substances, by revising subparagraph (TT) of paragraph (1) as follows: "(TT) ~~Methyl~~ 2-methyl-AP-237;"

SECTION 2.

Said chapter is further amended in Code Section 16-13-25, relating to Schedule I controlled substances, by revising subparagraph (CC) of paragraph (3) as follows: "(CC) Acetylpsilocin (4-acetoxy-N,N-dimethyltryptamine, 4-AcO-DMT); ~~Reserved;"~~

SECTION 3.

Said chapter is further amended in Code Section 16-13-25, relating to Schedule I controlled substances, by adding a new subparagraph to paragraph (4) to read as follows: "(A.5) Ethylphenidate;"

SECTION 4.

Said chapter is further amended in Code Section 16-13-25, relating to Schedule I controlled substances, by adding a new subdivision to division (13)(E)(ii) to read as follows: "(III) Tetrahydrothiophene group;"

SECTION 5.

Said chapter is further amended in Code Section 16-13-71, relating to dangerous drug, by adding new paragraphs to subsection (b) to read as follows: "(12.8) Acoramidis;" "(17.07) Afamitresgene autoleucel;" "(62.45) Aprocitentan;" "(63.3) Arimoclomol;" "(68.133) Atidarsagene autotemcel;" "(69.23) Axatilimab-csfr;" "(153.65) Ceftobiprole medocaril sodium;" "(206.6) Coagulation Factor IX (recombinant);" "(213.2) Concizumab-mtci;" "(216.5) Cosibelimab-ipdl;" "(217.3) Crinecerfont;" "(220.5) Crovalimab-akkz;" "(238.5) Danicopan;" "(256.58) Deuruxolitinib;" "(256.8) Deutivacaftor;" "(316.45) Donanemab-azbt;" "(331.0504) Eladocagene exuparvovec-tneq; (331.0506) Elafibranor;" "(331.0515) Elaparvovec-dzkt;" "(332.3) Enmetazobactam;" "(332.73) Ensartinib; (332.75) Ensifentrine;" "(380.45) Exagamglogene autotemcel;" "(402.3) Flurpiridaz F 18;" "(415.005) Givinostat;" "(464.9) Imetelstat;" "(466.8) Immune globulin, Human;" "(469.02) Inavolisib;" "(487.09) Iomeprol;" "(512.1) Landiolol;" "(513.03) Lazertinib; (513.07) Lebrikizumab-lbkz;" "(513.79) LetibotulinumtoxinA-wlbg;" "(514.3) Levacetylleucine;" "(520.1) Lifileucel;" "(530.3) Lovotibeglogene autotemcel;" "(540.47) Marstacimab-hncq;" "(540.8) Mavorixafor;" "(638.9) Nemolizumab-ilto;" "(649) Nogapendekin alfa inbakicept-pmln;" "(661.02) Obecabtagene autoleucel;" "(663.03) Olezarsen;" "(681.55) Palopegteriparatide;" "(692.5175) Pegulicianine;" "(835.7) Resmetirom;" "(836.75) Revumenib;" "(852.55) Seladelpar;" "(860.5) Smallpox and mpox (vaccinia) vaccine;" "(881.04) Sofpironium;" "(883.55) Sotatercept-csrk;" "(927.3) Sulopenem etzadroxil;" "(931.17) Tarlatamab-dlle;" "(967.625) Tislelizumab-jsgr;" "(973.55) Tovorafenib;" "(1021.65) Vadadustat;" "(1025.3) Vanzacaftor;" "(1037.4) Vorasidenib;" "(1039.05) Xanomeline;" "(1042.035) Zanidatamab-hrii;" "(1042.047) Zenocutuzumab-zbco;" "(1042.79) Zolbetuximab-clzb;"

SECTION 6.

Said chapter is further amended in Code Section 16-13-71, relating to dangerous drug, by adding a new subparagraph to paragraph (59) of subsection (b) to read as follows: "(ZZ.5) Peanut (arachis hypogaea) allergen powder-dnfp;"

SECTION 7.

This Act shall become effective upon its approval by the Governor or upon its becoming law without such approval.

SECTION 8.

All laws and parts of laws in conflict with this Act are repealed.